NOTE: For optimal resolution, posters should be printed on 11×17 paper.
2012
Tamburini et al. “IL-6-inducing Whole Yeast-based Immunotherapy Directly Controls IL-12 dependent CD8 T-cell Responses” J Immunother (2012) Vol. 35, Number 1, January 2012.
2011
Gameiro et al. “Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. “ Cancer Immunol Immunother (2011) 60:1227–1242.
Cereda et al. “Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.” Vaccine (2011) Jul 12;29(31):4992-9. Epub May 11, 2011.
Madan et al. “A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA: preliminary evidence of safety and immunologic activity” Poster Presentation; ASCO June 6, 2011.
D’Angelo et al. “GI-4000 vaccine as adjuvant consolidation therapy is immunogenic following definitive treatment in patients with stage I-III adenocarcinoma of the lung with KRAS mutations” Poster presentation; ASCO June 4, 2011.
Tanaka et al. “Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma” Gene Therapy (2011), 1–8; Online publication: March 10, 2011.
2010
Vierling et al. “GI-5005 Therapeutic Vaccine Improves Deficit in Cellular Immunity in IL28B Genotype T/T, Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 When Added to Standard of Care (SOC) Peg-IFN-Alfa2a/Ribavirin” Poster presentation; AASLD November 2, 2010.
Pockros et al. “GI-5005 Therapeutic Vaccine Plus Peg-IFN/Riba Improves sustained Virologic Response Versus Peg-IFN/Riba in Prior Non-Responders with Genotype 1 Chronic HCV Infection” ORAL presentation / poster handout; AASLD November 1, 2010.
Bui et al. “Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model” Vaccine 28 (2010) 6028-6035.
Ardiani et al. “Vaccines based on whole recombinant Saccharomyces cerevisiae cells” FEMS Yeast Res; (2010) 1-10.
Timcheva et al. “A Randomized Phase 2 Adjuvant Trial of Ras Positive Resected Pancreas Cancer Patients Treated with GI-4000 and Gemcitabine or Gemcitabine Alone: A safety Analysis of the First 100 Treated patients” Poster presentation; ESMO July 3, 2010.
Whiting et al. “Trials in Progress: A Randomized, Placebo Controlled, Multicenter Phase 2 Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000 Plus Gemcitabine versus Gemcitabine alone in Patients with Resected Pancreas Cancer with Activating Ras Mutations” Poster presentation; ASCO June 7, 2010.
McHutchison et al. “Pharmacogenomic Analysis Reveals Improved Virologic Response in All IL-28 B Genotypes in Naive Genotype 1 HCV Patients treated with GI-5005 Therapeutic Vaccine Plus PEG-IFN/Ribavirin” Poster presentation; EASL April 17, 2010.
Jacobson et al. “GI-5005 Therapeutic Vaccine Plus PEG-IFN/Ribavirin Significantly Improves Virologic Response and ALT Normalization at End-of-Treatment and Improves SVR24 Compared to PEG-IFN/ribavirin in Genotype-1 Chronic HCV Patients” Poster presentation; EASL April 15, 2010.
McHutchison et al. “GI-5005 Therapeutic Vaccine Plus PEG-IFN/Ribavirin Improves Biopsy Necro-Inflammatory Scores and ALT Normalization at 48 weeks Versus PEG-IFN/ribavirin in Genotype-1 Chronic HCV Patients” Poster presentation; EASL April 15, 2010.
Richards et al. “Randomized Phase 2 Adjuvant Trial of Resected Subjects with Ras Mutation Bearing Pancreas Cancer Treated with GI -4000 and Gemcitabine or Gemcitabine Alone: A Safety Analysis of the First 100 Treated Subjects” Poster presentation; ASCO-GI January 20, 2010.
2009
McHutchison et al. “GI-5005 Therapeutic Vaccine Plus Peg-IFN/Ribavirin Improves End of Treatment Response at 48 Weeks Versus Peg-IFN/Ribavirin in Naïve Genotype 1 Chronic HCV Patients” Poster presentation; AASLD November 2, 2009.
Boehm et al. “Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotyically and functionally distinct T-cell populations.” Can Immunol Immunother, August 2009.
Lawitz et al. “GI-5005 Immunotherapy Plus PEG-IFN/Ribavirin Versus PEG-IFN/Ribavirin in Genotype 1 Chronic HCV Subjects; Preliminary Phase 2 EVR Analyses“ Poster presentation; EASL April 24, 2009.
Boehm et al. “Concurrent Vaccination with Two Distinct Vaccine Platforms Targeting the Same Antigen Generates Phenotyically and Functionally Distinct T-cell Populations.” Poster Presentation; AACR April 23, 2009.
Gamerio et al. “Chemotherapy Can Enhance the Therapeutic Potential of Vaccine-Mediated Immunotherapy.” Poster Presentation; AACR April 23, 2009.
Britton et al. “Prospective use of an optimized ras mutation diagnostic in an adjuvant Phase 2 trial of mutation specific Ras-targeted immunotherapy (GI-4000) in pancreas cancer” Poster presentation; AACR April 21, 2009.
2008
McHutchison et al. “GI-5005 Immunotherapy Plus Peg-IFN/Ribavirin In Genotype 1 Chronic Hepatitis C Patients Compared To Peg-IFN/Ri bavirin Alone In Naive and Non-Responder Patients; Preliminary RVR and Viral Kinetic Analysis From the GI-5005-02 Phase 2 Study” Poster presentation; AASLD November 3, 2008.
Franzusoff et al. “Prevalence of K-Ras mutations in pancreas cancer and development of Ras-targeted immunotherapy” Poster presentation; EORTC-AACR-NCI October 21, 2008.
Guo et al. “Transnational Patterns of Pancreas Cancer Ras Mutations and Discovery of a New Ras Mutation with Oncogenic Synergy when Found with Ras Codon 12 Mutations” Poster presentation; AACR-NCI-EORTC, July 22, 2008.
Wansley et al. “Vaccination with a Recombinant Saccharomyces cerevisiae Expressing a Tumor Antigen Breaks Immune Tolerance and Elicits Therapeutic Antitumor Responses” Clinical Cancer Research. July 2008.
Munson et al. “Coupling Innate and Adaptive Immunity with Yeast-Based Cancer Immunotherapy” Chapter 9; Cancer Vaccines and Tumor Immunity. January 2008.
Haller et al. “Therapeutic and Prophylactic Viral Immunity in Animals and Humans.” Oral and Poster Presentation; Viral Immunity Conference, Keystone Symposia January 21, 2008.
Bernstein et al. “Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells.” Vaccine (2008) 26, 509-521.
2007
Schiff et al. “HCV-Specific Cellular Immunity, RNA Reductions, and Normalization of ALT in Chronic HCV Subjects after Treatment with GI-5005, a Yeast-Based Immunotherapy Targeting NS3 and Core: A Randomized, Double-blind, Placebo Controlled Phase 1b Study.” Poster presentation; AASLD, November 6, 2007, Boston MA.
Wansley et al. “Vaccination of CEA-transgenic mice with a recombinant Saccharomyces cerevisiae-CEA vaccine breaks immune tolerance and elicits therapeutic antitumor responses.” Poster presentation; AACR-NCI-EORTC, October 25, 2007, San Francisco, CA.
Remondo et al. “Recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen (CEA) activates human dendritic cells for CEA-specific T-cell reponses.” Poster presentation; AACR-NCI-EORTC, October 25, 2007, San Francisco, CA.
DeGregori et al. “Control of leukemia driven by the T315I escape mutation in Bc r-Abl with yeast-based Tarmogen immunotherapy.” Poster presentation; AACR-NCI-EORTC, October 25, 2007, San Francisco, CA.
Reimann et al. “Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1″ Experimental Dermatology 2007; 16: 814-822.
Guo et al. “Oncogenic synergy and a newly identified transforming ras mutation in human cancer” American Association for Cancer Research (AACR) 2007. Poster Presentation, Abstract LB-345; Los Angeles CA.
Haller et al. “Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins” Vaccine (2007) 25, 1452-1463.”
2006
Everson et al. “Interim Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Subjects with Chronic HCV After Treatment with GI-5005, a Yeast-based HCV Immunotherapy Targeting NS3 and Core Proteins.” American Association for the Study of Liver Disease (AASLD) 2006. Poster Presentation, October 30, 2006, Boston MA.
Franzusoff et al. “Yeast-based Tarmogen Immunotherapy Against Brain Tumors Expressing Self Antigens.” American Association for Cancer Research (AACR). Poster Presentation, April 2, 2006, Washington DC.
Haller et al. “Targeting Influenza with Yeast-Based Immunotherapy.” Keystone Symposia: Advances in Influenza Research: From Birds to Bench to Bedside. Poster Presentation, March 29, 2006, Steamboat CO.
Whiting et al.“Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: preliminary safety and immunogenicity results from a Phase 1 trial.“ ASCO Gastrointestinal Cancers Symposium. Poster Presentation, January 27, 2006, San Francisco CA.
2005
Haller et al. “Yeast Based Tarmogen Immunotherapy for Chronic HCV Infection“ 12th International Symposium on Hepatitis C and Related Viruses, Poster Presentation; October 2-6, 2005, Montreal Canada.
Cohn et al. “Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: preliminary safety and immunogenicity results from a Phase 1 trial.”ASCO 2005. Poster Presentation (Abstract 2571); Sunday May 15, 2005; Orlando FL.
Haller et al. “Preclinical Development of Yeast-Based Immunotherapy for Chronic Hepatitis Virus Infection.” 8th Annual Conference on Vaccine Research. Poster Presentation; May 9-11, 2005; Baltimore MD.
Franzusoff et al. “Yeast encoding tumor antigens in cancer immunotherapy.” (2005) Expert Opinion in Biological Therapy. 5(4); 565-575.
Fujita et al. “Whole recombinant yeast immunotherapeutic vaccine expressing human MART1 elicits protection against melanoma.” Keystone Symposia: Basic Aspects of Tumor Immunology II. Poster Presentation; March 19, 2005; Keystone CO.
Haller et al. “A Novel Yeast-based Immunotherapeutic for Chronic Hepatitis C Virus Infection” AASLD Single Topic Conference, Poster Presentation; March 4 2005, Chicago IL.
2004
Fujita et al. “Whole recombinant yeast immunotherapeutic protection against melanoma.” Cancer Vaccines 2004. Poster Presentation; October 5, 2004; New York NY.
Lu et al. “Mutation-selective tumor remission with ras-targeted, whole yeast-based immunotherapy.” (2004) Cancer Research 64, 5084-5088.
2001
Simpson. “Rising to the vaccine challenge.” (2001) Science 292, Number 5592, 1613.
Stubbs et al. “Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity.” (2001) Nature Medicine 7, 625-629